ANI Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2021. The filing was signed August 6, 2021. ANI develops, manufactures and markets branded and generic prescription drugs, with a focus on niche and complex products, and also provides contract manufacturing and development services.
Financial performance and liquidity
- Revenue: Second-quarter revenue was $48.6 million, up 0.3% year over year. First-half revenue was $103.1 million, up 5.0%.
- Revenue mix: Q2 generic sales were $34.2 million (+2.4%), branded sales $11.0 million (+3.8%), contract manufacturing $2.3 million (-19.9%), and royalty and other revenue $1.1 million (-30.6%). First-half royalty and other revenue rose to $12.9 million, mainly reflecting a one-time $11.2 million final Yescarta-related royalty.
- Profitability: Q2 operating loss was $15.6 million versus $11.3 million a year earlier; net loss was $14.1 million, or $1.17 per diluted share, versus $12.3 million, or $1.03 per share. First-half operating loss narrowed to $12.5 million from $19.1 million, and net loss to $14.0 million from $19.3 million.
- Margins: Q2 operating margin was -32.1% versus -23.4%; net margin was -29.1% versus -25.5%. First-half operating margin improved to -12.0% from -19.5%, and net margin to -13.5% from -19.7%. Management reported cost of sales, excluding depreciation and amortization and acquired-inventory fair-value effects, at 42.8% of Q2 revenue versus 39.8%; the comparable first-half measure was 39.6% versus 39.1%.
- Cash flow: First-half operating cash flow was $20.9 million, investing cash flow was -$22.7 million and financing cash flow was +$18.2 million. Cash and cash equivalents were $24.3 million at June 30; including restricted cash, the total was $29.3 million.
- Debt and liquidity: Gross borrowings under the existing credit facility were $205.7 million, including $31.5 million drawn on the revolver. $43.5 million remained available under the $75 million revolver. The company reported $89.5 million of current assets and $89.5 million of current liabilities? The balance sheet reports current assets of $191.8 million and current liabilities of $89.5 million. ANI said available resources should meet working-capital needs and debt obligations for at least 12 months.
- Other balance-sheet items: Total assets were $480.2 million, total liabilities $288.2 million and stockholders’ equity $191.9 million. Inventory was $67.6 million, up from $60.8 million at year-end.
Material changes versus the prior comparable period
- Q2 revenue was broadly flat, while first-half revenue growth largely reflected the final $11.2 million Yescarta-related royalty. ANI said it does not expect future royalty income under that license agreement.
- Generic and branded sales declined for the first half, affected by product-specific volume declines and lower average selling prices or shifts to lower-priced product mix; Q2 sales in both categories increased year over year. Management also cited a recovery in prescription levels during Q2.
- Q2 results included an $8.4 million legal settlement expense. Lower Cortrophin pre-launch charges and lower R&D spending helped first-half expenses, while Novitium transaction costs and Cortrophin commercialization spending increased SG&A.
- Operating cash flow decreased by $1.7 million year over year, partly due to income-tax payments. Investing outflows were substantially lower than in 2020, when ANI acquired Amerigen assets.
Outlook, significant events and risks
- Novitium acquisition: The proposed acquisition remained subject to FTC review and other closing conditions as of the filing. ANI expected a second-half 2021 closing. Consideration included an estimated $89.5 million cash payment, 2,466,667 common shares and up to $46.5 million in earn-outs. Financing was planned through a new $340 million secured facility, a $25 million preferred-stock PIPE investment and equity issuance. The transaction could increase debt, dilute existing shareholders and create integration and execution risks.
- Cortrophin: ANI resubmitted the Cortrophin Gel supplemental NDA to the FDA in Q2 after a 2020 refusal-to-file letter. The filing gives no clear approval date or quantified launch guidance. Pre-launch materials are expensed before FDA approval, and ANI said their eventual commercial usability is uncertain.
- Legal matters: ANI recorded an $8.4 million charge for its Arbor settlement; the agreement was reached August 3, 2021 and paid from cash after quarter-end. Other matters include Bystolic antitrust litigation, a vancomycin patent suit, and a continuing federal generic-drug-industry investigation. The filing does not provide a clear estimate of possible losses for these matters.
- COVID-19 and operations: ANI reported minor supply-chain disruptions but no significant manufacturing impact. It cautioned that pandemic duration, future outbreaks and related economic effects remain uncertain.
- Other risks: The company relies on single-source qualified API suppliers for some products; certain marketed products lack approved NDAs or ANDAs. Customer concentration is significant: three customers represented 74% of Q2 revenue and 86% of accounts receivable at June 30. ANI also cited pricing pressure, regulatory and approval risks, competition, litigation and interest-rate exposure.
Key facts investors should verify
- Whether the Novitium acquisition closed, its final purchase price and financing terms, and resulting debt and share dilution.
- FTC review status and any conditions affecting the transaction or anticipated benefits.
- FDA review progress and any approval or launch timing for Cortrophin Gel, including the implications of continued pre-launch spending.
- Underlying revenue trends excluding the one-time Yescarta royalty, including pricing, volumes, product mix and customer concentration.
- Debt balances, covenant compliance and liquidity after the Arbor settlement and any acquisition financing.
- Developments in Bystolic, patent and other legal matters and the generic-industry investigation.